Laurion Capital Management’s AnaptysBio ANAB Stock Holding History

Laurion Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-209,002	Closed	-$4.25M	–	490
2023 Q2	$4.25M	Sell	209,002 -54,206	-21%	-$1.1M	0.02%	266
2023 Q1	$5.73M	Hold	263,208	–	–	0.04%	230
2022 Q4	$8.16M	Hold	263,208	–	–	0.04%	241
2022 Q3	$6.71M	Hold	263,208	–	–	0.04%	226
2022 Q2	$5.34M	Buy	263,208 +55,708	+27%	+$1.23M	0.08%	155
2022 Q1	$5.13M	Buy	207,500 +32,500	+19%	+$984K	0.06%	163
2021 Q4	$6.08M	Buy	+175,000	New	+$5.55M	0.06%	179
2019 Q4	–	Sell	-11,500	Closed	-$402K	–	881
2019 Q3	$402K	Buy	+11,500	New	+$547K	﹤0.01%	804
2019 Q1	–	Sell	-27,714	Closed	-$1.77M	–	835
2018 Q4	$1.77M	Buy	27,714 +12,460	+82%	+$927K	0.03%	457
2018 Q3	$1.52M	Buy	+15,254	New	+$1.27M	0.01%	594
2018 Q1	–	Sell	-4,125	Closed	-$415K	–	1309
2017 Q4	$415K	Buy	+4,125	New	+$304K	﹤0.01%	1228

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Laurion Capital Management's ANAB Position: Q3 2023 in Review

Laurion Capital Management sold out of AnaptysBio (ANAB) in Q3 2023, closing a stake of 209,002 shares — an estimated $4.25M sold.

Laurion Capital Management first reported a position in ANAB in Q4 2017 and held it in 11 quarters. The position peaked at $8.16M in Q4 2022. 116 funds tracked by Wall St. Rank hold ANAB as of Q3 2023.

Laurion Capital Management reported no remaining AnaptysBio position as of Q3 2023 after selling out during the quarter.
Laurion Capital Management sold 209,002 AnaptysBio shares in Q3 2023, an estimated $4.25M.
Laurion Capital Management first reported a position in AnaptysBio in Q4 2017 and held it in 11 quarters.
Laurion Capital Management's AnaptysBio position peaked at $8.16M in Q4 2022.
116 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.